Hartman Institute for Therapeutic Organ Regeneration

Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization.

TitleEndothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization.
Publication TypeJournal Article
Year of Publication2011
AuthorsDing B-S, Nolan DJ, Guo P, Babazadeh AO, Cao Z, Rosenwaks Z, Crystal RG, Simons M, Sato TN, Worgall S, Shido K, Rabbany SY, Rafii S
JournalCell
Volume147
Issue3
Pagination539-53
Date Published2011 Oct 28
ISSN1097-4172
KeywordsAnimals, Endothelial Cells, Endothelial Growth Factors, Epithelial Cells, Lung, Matrix Metalloproteinase 14, Mice, Mice, Knockout, Neovascularization, Physiologic, Pneumonectomy, Pulmonary Alveoli, Receptor, Fibroblast Growth Factor, Type 1, Regeneration, Stem Cells, Tissue Culture Techniques, Vascular Endothelial Growth Factor Receptor-2
Abstract

<p>To identify pathways involved in adult lung regeneration, we employ a unilateral pneumonectomy (PNX) model that promotes regenerative alveolarization in the remaining intact lung. We show that PNX stimulates pulmonary capillary endothelial cells (PCECs) to produce angiocrine growth factors that induce proliferation of epithelial progenitor cells supporting alveologenesis. Endothelial cells trigger expansion of cocultured epithelial cells, forming three-dimensional angiospheres reminiscent of alveolar-capillary sacs. After PNX, endothelial-specific inducible genetic ablation of Vegfr2 and Fgfr1 in mice inhibits production of MMP14, impairing alveolarization. MMP14 promotes expansion of epithelial progenitor cells by unmasking cryptic EGF-like ectodomains that activate the EGF receptor (EGFR). Consistent with this, neutralization of MMP14 impairs EGFR-mediated alveolar regeneration, whereas administration of EGF or intravascular transplantation of MMP14(+) PCECs into pneumonectomized Vegfr2/Fgfr1-deficient mice restores alveologenesis and lung inspiratory volume and compliance function. VEGFR2 and FGFR1 activation in PCECs therefore increases MMP14-dependent bioavailability of EGFR ligands to initiate and sustain alveologenesis.</p>

DOI10.1016/j.cell.2011.10.003
Alternate JournalCell
PubMed ID22036563
PubMed Central IDPMC3228268
Grant ListP50 HL084936-04 / HL / NHLBI NIH HHS / United States
RC1 AI080309-01 / AI / NIAID NIH HHS / United States
R01 HL053793 / HL / NHLBI NIH HHS / United States
R01 HL097797-03 / HL / NHLBI NIH HHS / United States
P50 HL084936 / HL / NHLBI NIH HHS / United States
P50 HL084936-02 / HL / NHLBI NIH HHS / United States
P50 HL084936-05 / HL / NHLBI NIH HHS / United States
RC2 HL101846-01 / HL / NHLBI NIH HHS / United States
R01 HL097797-01 / HL / NHLBI NIH HHS / United States
R01HL53793 / HL / NHLBI NIH HHS / United States
RC1 AI080309 / AI / NIAID NIH HHS / United States
P50 HL084936-01 / HL / NHLBI NIH HHS / United States
RC2 HL101846-02 / HL / NHLBI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
R01 HL097797-02 / HL / NHLBI NIH HHS / United States
R01 HL097797 / HL / NHLBI NIH HHS / United States
R01 HL097797-04 / HL / NHLBI NIH HHS / United States
P50 HL084936-03 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065